Urology
-
To evaluate the disease and treatment-related factors for predicting biochemical freedom from recurrence (BFR) in patients with clinically localized prostate cancer undergoing permanent prostate brachytherapy. ⋯ The quality of permanent prostate brachytherapy as measured by the D(90) was the most significant predictor for BFR in this study cohort at 10 years. Furthermore, adding external beam radiotherapy and/or hormonal therapy as adjuvant therapies did not independently predict for BFR. Overall, the reported 10-year BFR rates in this study were favorable. Strategies for ensuring the best quality implant should be used and, when reporting brachytherapy outcomes, the implant quality should be noted.